Phase II Clinical Trial to Begin This Year
StemCells, Inc. yesterday announced that, based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study.
Exceeding the company’s expectations, interim results showed a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease. This was after a single dose of the company’s proprietary HuCNS-SC® human neural stem cells. In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC® as a treatment for dry AMD. Final results are expected to be released mid-2015.
Source: Market Watch
